×
About 13,318 results

ALLMedicine™ Myelodysplastic Syndromes Center

Research & Reviews  6,335 results

Hypomethylating agents (HMA) for the treatment of acute myeloid leukemia and myelodyspl...
https://doi.org/10.1038/s41375-021-01218-0 10.1038/nrc3130 10.1038/nrg1655 10.1038/295620a0 10.1016/S0092-8674(00)81656-6 10.1007/BF02135399 10.1002/cncr.21792 10.1200/JCO.2010.30.9245 10.1200/JCO.2008.19.6550 10.1182/blood-2015-01-621664 10.1200/JCO.2011.38.9429 10.1186/s13148-016-0237-y 10.1158/1535-7163.MCT-08-0743 10.1248/bpb.b14-00622 10.1177/0091270004271947 10.1007/s00280-007-0531-7 10.1158/1078-0432.CCR-12-1722 10.1021/tx900131u 10.1016/0092-8674(92)90561-P 10.1128/MCB.25.11.4727-4741.2005 10.1093/nar/gkq187 10.1158/1078-0432.CCR-08-2783 10.1016/j.cell.2015.07.056 10.1016/j.cell.2015.07.011 10.1053/j.seminhematol.2019.02.001 10.1056/NEJMoa1605949 10.1016/j.leukres.2017.10.013 10.18632/oncotarget.25328 10.1038/sj.leu.2404796 10.1200/JCO.2011.35.8135 10.1182/blood-2008-02-140038 10.1016/j.exphem.2013.12.004 10.1038/s41375-020-0973-z 10.1371/journal.pone.0023372 10.1038/leu.2013.330 10.1038/leu.2017.340 10.1038/s41467-019-11413-4 10.1016/j.celrep.2017.06.067 10.1172/JCI78752 10.1007/s00432-019-03016-9 10.1038/s41467-018-03513-4 10.1038/ncomms10767 10.1038/leu.2016.282 10.1038/leu.2012.312 10.1158/0008-5472.CAN-19-1696 10.18632/oncotarget.481 10.18632/oncotarget.17482 10.1038/s41568-019-0109-9 10.1111/bjh.16228 10.1016/j.cell.2017.06.007 10.1182/blood-2009-03-210393 10.1182/blood-2011-09-377044 10.1182/blood-2014-05-572743 10.18632/oncotarget.6213 10.1002/ijc.25635 10.1182/blood-2015-11-680546 10.1186/s40164-020-00178-y 10.1007/s00262-012-1204-x 10.1073/pnas.1410626111 10.1186/s12865-020-0337-5 10.1182/bloodadvances.2018022053 10.1038/leu.2013.355 10.18632/oncotarget.3324 10.1080/10428190701882146 10.3109/10428194.2014.966708 10.1016/j.leukres.2015.02.004 10.1016/S1470-2045(15)00038-8 10.1016/S1470-2045(17)30576-4 10.1016/S2352-3026(19)30029-8 10.1182/blood-2019-127253 10.1016/S2352-3026(19)30030-4 10.1182/blood.2019004143 10.1182/blood-2019-122980 10.1007/s11523-020-00709-x 10.1056/NEJMoa2004444 10.1016/j.bbmt.2018.06.016 10.3324/haematol.2018.203885 10.1200/JCO.2013.50.3102 10.1371/journal.pone.0135520 10.1073/pnas.1002650107 10.3109/10428194.2012.762093 10.1016/j.stem.2012.12.013 10.1038/s41591-018-0233-1 10.1158/1078-0432.CCR-19-1900 10.1056/NEJMoa2012971 10.1182/blood.2019003988 10.1158/2159-8290.CD-19-0710 10.1126/scitranslmed.aax2863 10.1200/JCO.19.01053 10.1016/j.biopha.2020.109878 10.1007/s00277-016-2681-3 10.3324/haematol.2014.115055 10.3389/fphar.2018.01380 10.1002/cncr.29085 10.1158/1078-0432.CCR-17-1423 10.1038/s41375-018-0070-8 10.3324/haematol.2017.172353 10.1200/JCO.2015.66.2510 10.1182/bloodadvances.2018023689 10.1182/bloodadvances.2020002846 10.1182/blood-2020-142687 10.1016/j.cell.2016.03.045 10.1016/S1470-2045(16)00009-7 10.1016/j.leukres.2020.106369 10.1182/blood-2010-11-320093 10.1038/s41467-019-12983-z 10.1038/leu.2013.7 10.1038/bmt.2015.10 10.1182/blood-2017-06-789800 10.1182/blood-2018-03-841171 10.1182/blood-2014-03-560557 10.1158/1078-0432.CCR-17-1201 10.1038/s41467-017-02630-w 10.1016/j.leukres.2015.06.007 10.4049/jimmunol.1502399 10.1016/j.jneuroim.2018.05.013 10.3324/haematol.2012.074823 10.4049/jimmunol.169.8.4253 10.1016/j.molimm.2009.02.033 10.1016/j.exphem.2011.08.004 10.1007/s00432-017-2394-6 10.1038/srep08020
Leukemia Stomper J, Rotondo JC et. al.

May 7th, 2021 - Aberrant DNA methylation plays a pivotal role in tumor development and progression. DNA hypomethylating agents (HMA) constitute a class of drugs which are able to reverse DNA methylation, thereby triggering the re-programming of tumor cells. The f...

Bone marrow mesenchymal stromal cells in chronic myelomonocytic leukaemia: overactivate...
https://doi.org/10.1111/bjh.17425
British Journal of Haematology; Xu R, Huang X et. al.

May 7th, 2021 - Sophisticated cross-talk between bone marrow mesenchymal stromal cells (BM MSCs) and haematopoietic/leukaemic stem cells in patients with myelodysplastic syndromes (MDS) and myeloid leukaemia have been emphasized in previous reports. However, mese...

Multiplex ligation-dependent probe amplification and fluorescence in situ hybridization...
https://doi.org/10.1097/MD.0000000000025768
Medicine Ai X, Li B et. al.

May 5th, 2021 - This study aimed to compare interphase fluorescence in situ hybridization (iFISH) and multiplex ligation dependent probe amplification (MLPA) for identifying genetic changes in myelodysplastic syndromes (MDS).The frequencies of cytogenetic changes...

Computational flow cytometry as a diagnostic tool in suspected-myelodysplastic syndromes.
https://doi.org/10.1002/cyto.a.24360
Cytometry. Part A : the Journal of the International Soci... Duetz C, Van Gassen S et. al.

May 4th, 2021 - The diagnostic work-up of patients suspected for myelodysplastic syndromes is challenging and mainly relies on bone marrow morphology and cytogenetics. In this study, we developed and prospectively validated a fully computational tool for flow cyt...

Myelodysplastic syndrome and immunotherapy novel to next in-line treatments.
https://doi.org/10.1080/21645515.2021.1898307
Human Vaccines & Immunotherapeutics; Linder K, Lulla P

May 4th, 2021 - Patients with Myelodysplastic syndromes (MDS) have few therapy options for sustainable responses in the frontline setting, and even less after hypomethylating agent (HMA) failure in relapsed and refractory setting. The only potential cure is an al...

see more →

Guidelines  31 results

Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment a...
https://doi.org/10.1016/j.annonc.2020.11.002
Annals of Oncology : Official Journal of the European Soc... Fenaux P, Haase D et. al.

Nov 22nd, 2020 - Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†☆.|2020|Fenaux P,Haase D,Santini V,Sanz GF,Platzbecker U,|diagnosis,epidemiology,therapy,

Considerable Variation Exists in Receipt of Complete Diagnostic Evaluations for Myelodysplastic Syndromes Among Medicare Patients
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200129/full/

May 12th, 2020 - A substantial proportion of Medicare patients with myelodysplastic syndromes (MDS) do not undergo a complete diagnostic evaluation (CDE), including a bone marrow biopsy, to confirm their disease (Abstract 7555).

Hematology Quality Metrics
http://www.hematology.org/Clinicians/Guidelines-Quality/503.aspx
Allen, S.

Feb 20th, 2018 - These clinical performance measures are designed for individual quality improvement. Some of the measures may also be appropriate for accountability if appropriate sample sizes and implementation rules are achieved.

Myelodysplastic Syndromes, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.
https://doi.org/10.6004/jnccn.2017.0007
Journal of the National Comprehensive Cancer Network : JN... Greenberg PL, Stone RM et. al.

Jan 3rd, 2017 - The myelodysplastic syndromes (MDS) comprise a heterogenous group of myeloid disorders with a highly variable disease course. Diagnostic criteria to better stratify patients with MDS continue to evolve, based on morphology, cytogenetics, and the p...

Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from...
http://www.bloodjournal.org/content/122/17/2943
Malcovati, L.,et al.

Oct 23rd, 2013 - Within the myelodysplastic syndrome (MDS) work package of the European LeukemiaNet, an Expert Panel was selected according to the framework elements of the National Institutes of Health Consensus Development Program. A systematic review of the lit.

see more →

Drugs  59 results see all →

Clinicaltrials.gov  6,595 results

Hypomethylating agents (HMA) for the treatment of acute myeloid leukemia and myelodyspl...
https://doi.org/10.1038/s41375-021-01218-0 10.1038/nrc3130 10.1038/nrg1655 10.1038/295620a0 10.1016/S0092-8674(00)81656-6 10.1007/BF02135399 10.1002/cncr.21792 10.1200/JCO.2010.30.9245 10.1200/JCO.2008.19.6550 10.1182/blood-2015-01-621664 10.1200/JCO.2011.38.9429 10.1186/s13148-016-0237-y 10.1158/1535-7163.MCT-08-0743 10.1248/bpb.b14-00622 10.1177/0091270004271947 10.1007/s00280-007-0531-7 10.1158/1078-0432.CCR-12-1722 10.1021/tx900131u 10.1016/0092-8674(92)90561-P 10.1128/MCB.25.11.4727-4741.2005 10.1093/nar/gkq187 10.1158/1078-0432.CCR-08-2783 10.1016/j.cell.2015.07.056 10.1016/j.cell.2015.07.011 10.1053/j.seminhematol.2019.02.001 10.1056/NEJMoa1605949 10.1016/j.leukres.2017.10.013 10.18632/oncotarget.25328 10.1038/sj.leu.2404796 10.1200/JCO.2011.35.8135 10.1182/blood-2008-02-140038 10.1016/j.exphem.2013.12.004 10.1038/s41375-020-0973-z 10.1371/journal.pone.0023372 10.1038/leu.2013.330 10.1038/leu.2017.340 10.1038/s41467-019-11413-4 10.1016/j.celrep.2017.06.067 10.1172/JCI78752 10.1007/s00432-019-03016-9 10.1038/s41467-018-03513-4 10.1038/ncomms10767 10.1038/leu.2016.282 10.1038/leu.2012.312 10.1158/0008-5472.CAN-19-1696 10.18632/oncotarget.481 10.18632/oncotarget.17482 10.1038/s41568-019-0109-9 10.1111/bjh.16228 10.1016/j.cell.2017.06.007 10.1182/blood-2009-03-210393 10.1182/blood-2011-09-377044 10.1182/blood-2014-05-572743 10.18632/oncotarget.6213 10.1002/ijc.25635 10.1182/blood-2015-11-680546 10.1186/s40164-020-00178-y 10.1007/s00262-012-1204-x 10.1073/pnas.1410626111 10.1186/s12865-020-0337-5 10.1182/bloodadvances.2018022053 10.1038/leu.2013.355 10.18632/oncotarget.3324 10.1080/10428190701882146 10.3109/10428194.2014.966708 10.1016/j.leukres.2015.02.004 10.1016/S1470-2045(15)00038-8 10.1016/S1470-2045(17)30576-4 10.1016/S2352-3026(19)30029-8 10.1182/blood-2019-127253 10.1016/S2352-3026(19)30030-4 10.1182/blood.2019004143 10.1182/blood-2019-122980 10.1007/s11523-020-00709-x 10.1056/NEJMoa2004444 10.1016/j.bbmt.2018.06.016 10.3324/haematol.2018.203885 10.1200/JCO.2013.50.3102 10.1371/journal.pone.0135520 10.1073/pnas.1002650107 10.3109/10428194.2012.762093 10.1016/j.stem.2012.12.013 10.1038/s41591-018-0233-1 10.1158/1078-0432.CCR-19-1900 10.1056/NEJMoa2012971 10.1182/blood.2019003988 10.1158/2159-8290.CD-19-0710 10.1126/scitranslmed.aax2863 10.1200/JCO.19.01053 10.1016/j.biopha.2020.109878 10.1007/s00277-016-2681-3 10.3324/haematol.2014.115055 10.3389/fphar.2018.01380 10.1002/cncr.29085 10.1158/1078-0432.CCR-17-1423 10.1038/s41375-018-0070-8 10.3324/haematol.2017.172353 10.1200/JCO.2015.66.2510 10.1182/bloodadvances.2018023689 10.1182/bloodadvances.2020002846 10.1182/blood-2020-142687 10.1016/j.cell.2016.03.045 10.1016/S1470-2045(16)00009-7 10.1016/j.leukres.2020.106369 10.1182/blood-2010-11-320093 10.1038/s41467-019-12983-z 10.1038/leu.2013.7 10.1038/bmt.2015.10 10.1182/blood-2017-06-789800 10.1182/blood-2018-03-841171 10.1182/blood-2014-03-560557 10.1158/1078-0432.CCR-17-1201 10.1038/s41467-017-02630-w 10.1016/j.leukres.2015.06.007 10.4049/jimmunol.1502399 10.1016/j.jneuroim.2018.05.013 10.3324/haematol.2012.074823 10.4049/jimmunol.169.8.4253 10.1016/j.molimm.2009.02.033 10.1016/j.exphem.2011.08.004 10.1007/s00432-017-2394-6 10.1038/srep08020
Leukemia Stomper J, Rotondo JC et. al.

May 7th, 2021 - Aberrant DNA methylation plays a pivotal role in tumor development and progression. DNA hypomethylating agents (HMA) constitute a class of drugs which are able to reverse DNA methylation, thereby triggering the re-programming of tumor cells. The f...

Bone marrow mesenchymal stromal cells in chronic myelomonocytic leukaemia: overactivate...
https://doi.org/10.1111/bjh.17425
British Journal of Haematology; Xu R, Huang X et. al.

May 7th, 2021 - Sophisticated cross-talk between bone marrow mesenchymal stromal cells (BM MSCs) and haematopoietic/leukaemic stem cells in patients with myelodysplastic syndromes (MDS) and myeloid leukaemia have been emphasized in previous reports. However, mese...

Multiplex ligation-dependent probe amplification and fluorescence in situ hybridization...
https://doi.org/10.1097/MD.0000000000025768
Medicine Ai X, Li B et. al.

May 5th, 2021 - This study aimed to compare interphase fluorescence in situ hybridization (iFISH) and multiplex ligation dependent probe amplification (MLPA) for identifying genetic changes in myelodysplastic syndromes (MDS).The frequencies of cytogenetic changes...

Computational flow cytometry as a diagnostic tool in suspected-myelodysplastic syndromes.
https://doi.org/10.1002/cyto.a.24360
Cytometry. Part A : the Journal of the International Soci... Duetz C, Van Gassen S et. al.

May 4th, 2021 - The diagnostic work-up of patients suspected for myelodysplastic syndromes is challenging and mainly relies on bone marrow morphology and cytogenetics. In this study, we developed and prospectively validated a fully computational tool for flow cyt...

Myelodysplastic syndrome and immunotherapy novel to next in-line treatments.
https://doi.org/10.1080/21645515.2021.1898307
Human Vaccines & Immunotherapeutics; Linder K, Lulla P

May 4th, 2021 - Patients with Myelodysplastic syndromes (MDS) have few therapy options for sustainable responses in the frontline setting, and even less after hypomethylating agent (HMA) failure in relapsed and refractory setting. The only potential cure is an al...

see more →

News  289 results

Whole-Genome Sequencing Emerging for Routine Cancer Care
https://www.medscape.com/viewarticle/947261

Mar 10th, 2021 - Almost 20 years after the human genome was first mapped, whole-genome sequencing might finally be ready to enter routine cancer care. Researchers at Washington University in St. Louis, St. Louis, Missouri, are commercializing an automated sequenci...

Myelodysplastic Syndromes Clinical Practice Guidelines (ESMO, 2021)
https://reference.medscape.com/viewarticle/944879

Feb 2nd, 2021 - Guidelines on the diagnosis and treatment of myelodysplastic syndromes were published in November 2020 by the European Society of Medical Oncology.[1] The diagnosis of myelodysplastic syndromes (MDS) is based on the blood count, the marrow aspirat...

FDA Approves Oral Therapy for Myelodysplastic Syndromes, CMML
https://www.medscape.com/viewarticle/933602

Jul 7th, 2020 - The Food and Drug Administration has approved Inqovi (decitabine and cedazuridine tablets, Astex Pharmaceuticals) to treat adults with myelodysplastic syndromes (MDS) or chronic myelomonocytic leukemia (CMML). The agency's action gives physicians ...

Considerable Variation Exists in Receipt of Complete Diagnostic Evaluations for Myelodysplastic Syndromes Among Medicare Patients
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200129/full/

May 12th, 2020 - A substantial proportion of Medicare patients with myelodysplastic syndromes (MDS) do not undergo a complete diagnostic evaluation (CDE), including a bone marrow biopsy, to confirm their disease (Abstract 7555).

First Advance in MDS for Decade: Luspatercept for Anemia
https://www.medscape.com/viewarticle/928198

Apr 5th, 2020 - The US Food and Drug Administration (FDA) has approved luspatercept (Reblozyl, Bristol-Myers Squibb/Acceleron) for the treatment of anemia in patients with myelodysplastic syndromes (MDS). The green light represents the first treatment advancement...

see more →

Patient Education  9 results see all →